Paper Details

  1. Home
  2. Paper Details

'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.

Author: DavisJames A, DucoMarissa, GaffneyKelly, HashmiHamza, YoungbergHeather

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Daratumumab is an anti-CD38 monoclonal antibody used to treat multiple myeloma and AL amyloidosis. Subcutaneous administration is associated with fewer infusion-related reactions and shorter infusion times compared to intravenous administration.
Paper Details　
Original Abstract of the Article :
Daratumumab, an anti-CD38 monoclonal antibody, is a key component in the treatment paradigms of multiple myeloma and AL amyloidosis in both the newly diagnosed and relapsed and/or refractory setting. Intravenous (IV) daratumumab administration requires extended infusion times and is associated with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2022.03.006

データ提供：米国国立医学図書館（NLM）

Daratumumab: A Fast and Efficient Treatment for Multiple Myeloma

The desert of multiple myeloma can be a challenging place to navigate, with its relentless progression and often debilitating side effects. This study explores the use of daratumumab, an anti-CD38 monoclonal antibody, as a treatment for multiple myeloma.

The researchers found that subcutaneous administration of daratumumab was both safe and cost-effective, with shorter observation times compared to intravenous administration. This is good news for patients who may find the intravenous route time-consuming and uncomfortable. The researchers also observed that subcutaneous administration was associated with lower rates of infusion-related reactions. It's like finding a shortcut through the desert - it's faster, easier, and less stressful.

A More Convenient and Effective Treatment Option

This study highlights the advantages of subcutaneous administration of daratumumab for patients with multiple myeloma. It offers a more convenient and efficient treatment option, with fewer side effects. The researchers found that the shorter observation times associated with subcutaneous administration did not compromise safety. It's like finding a cool oasis in the heat of the desert - it offers relief without sacrificing the benefits of the journey.

Hope for a Smoother Journey

This study offers hope for patients with multiple myeloma by providing a more convenient and effective treatment option. The researchers' findings could lead to improved patient outcomes and a better quality of life. It's like finding a new trail in the desert - it offers a smoother and more enjoyable journey.

Dr.Camel's Conclusion

This study demonstrates the potential of subcutaneous daratumumab for the treatment of multiple myeloma. It offers a promising alternative to intravenous administration, with the potential to improve patient comfort and outcomes.

Date :
  1. Date Completed 2022-07-19
  2. Date Revised 2022-08-18
Further Info :

Pubmed ID

35414476

DOI: Digital Object Identifier

10.1016/j.clml.2022.03.006

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.